CMB International Securities  Equity Research  Company Update
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
ACCESS KEY TO OUR REPORTS ON BLOOMBERG CMBR
China FB Sector
Mkt Cap (HK mn)
Avg 3 mths to (HK mn)
52w HighLow (HK)
Total Issued Shares (mn)
Source Bloomberg
Shareholding Structure
Source HKEx
Source Bloomberg
12-mth Price Performance
Source Bloomberg
Auditor Da Hua
China Dairy Sector  - Multiple growth
drivers ahead sector consolidation to
continue  19 Nov 2019
BUY (Maintain)
(Previous TP
UpDownside
4 May 2020
FY19 NP 8% to RMB6934mn in line with our estimates and consensus 1Q20
NP was down 50% due to COVID-19 impact That said management said sales
recovered 90% currently and expects a full recovery by Jun 2020 We cut our
FY2021E net profit estimates by 17%5% mainly to reflect lower revenue and
GPM Our TP is revised from RMB3404 to RMB3310 based on 280x average
FY20E and FY21E EPS We expect Yili would benefit from industry consolidation
reflected by market share gain in 1Q20 Maintain Buy
 FY19 results in line Revenue rose 14% in line led by liquid milk (12%)
and milk powder (25%) Key products like Satine and Ambrosial grew by 17-
18% behind MNs Milk Deluxe and Just Yoghurts 20% growth Market share
of UHT milk and IMF rose 14ppt and 04ppt to 377% and 60% respectively
in 2019 GPM fell 05ppt to 373% slight below our expectation of 378% led
by 67ppt reduction in GPM of milk powder segment mainly due to margin
dilution from the acquisition of Westland Co-operative Dairy SGA expenses
ratio dropped 06ppt to 282% led by 16ppt reduction in AP expenses
 1Q20 hit by COVID-19 Revenue dropped 11% led by 19% decline of liquid
milk sales as sales affected by COVID-19 Market share of UHT milk and
chilled milk up 11ppt and 03ppt YoY GPM squeezed by 24ppt to 375% on
more promotion to destock old inventories SGA expenses ratio increased
16ppt due to operating deleverage Yili reported RMB67mn net finance cost
2019 to RMB12bn in Mar 2020 NP fell 50% to RMB1143mn
 FY20E guidance Yili sets its total revenue and PBT target at RMB97bn and
RMB61bn in FY20E representing 75% YoY growth and 26% YoY decrease
respectively This implies 14% YoY growth13% YoY decline for total
revenuePBT respectively during 2-4Q20 That said excluding government
grant and share award expenses management expects adj NP to resume
growth in 2-4Q20 Going forward while Yili still focuses on domestic dairy
business it will develop Southeast Asia market and develop healthy drinks
 Maintain Buy Our new TP of RMB3310 is based on 280x average FY20E
and FY21E EPS Our target PE multiple is unchanged as we expect Yili to
resume double-digit revenue growth beginning 2H20E Catalysts better-
than-expected revenue and margins Risks recovery slower-than-expected
raw milk cost pressure food safety issues
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
Net profit (RMB mn)
YoY growth (%)
Consensus EPS (RMB)
Source Company data Bloomberg CMBIS estimates
Yili (600887 CH)
Expect full recovery of sales by Jun
4 May 2020
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 FY19 and 1Q20 results review
Source Company CMBIS
YE Dec (RMB mn)
Key products like Satine Ambrosial and plain milk
saw 17-18% growth according to Nielsen data
Selling and distribution expenses
Administrative expenses
increased due to acquisition of new businesses set up of
new business units salary increase and share award exp
RD expenses
Tax  surcharges
total borrowing jumped from RMB156bn to RMB684bn
Other gains(losses)
Share of profit from JVassociate
Non-controlling interests
Margin  Ratio (%)
raw milk cost 67% dilution from acquisition of Westland
Co-operative Dairy
Selling expenses expenses ratio
AP exp ratio fell 16ppt to 123%
Administrateive expenses ratio
RD expenses ratio
FY18 change
AC receivables days
AC payable days
dU9UpWuWgZlWlXcVxUoOpM9P9R9PsQpPpNrRfQmMqNeRpPoQ7NpOtPwMnOsPwMqQtP
4 May 2020
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 2 Earnings revision
Source Company data CMBIS estimates
Figure 3 CMBIS estimates vs consensus
Source Bloomberg CMBIS estimates
Figure 4 PE band chart
Source CMBIS estimates Bloomberg Company data
4 May 2020
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E  YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E
97074 109902 120994  Profit before tax
97467  JV  associates
14999  DA
850  Change in working capital
45906  Operating cash flow
927  Capex
(19773) (21070) (23298) (25772) (28313)  Acquisitions
(5808)  Others
(1868)  Investing cash flow
(39)  Dividend and interest paid
Other gains(losses)
(86)  Others
JV  associates
274  Financing cash flow
Pre-tax profit
(1672)  Net change in cash
Less Minority interests
(17)  Cash at the beginning
9305  Exchange difference
YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E  YE 31 Dec
FY18A FY19A FY20E FY21E FY22E
Non-current assets
Prepaid lease payments
2701   Ice-cream
Other non-current assets
Quick ratio (x)
AC receivables days
AC payables days
Net cash (RMB mn)
Non-current liabilities
5255  Returns (%)
Shareholders equity
Non-controlling interests
BVPS (RMB)
Source Company data CMBIS estimates
4 May 2020
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
in this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve
covered in this report
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIS
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Securities Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Securities Limited (CMBIS) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary
of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors
CMBIS does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives
financial position or special requirements  Past performance has no indication of future performance and actual events may differ materially from
that which is contained in the report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a
independently evaluate particular investments and strategies and encourages investors to consult with a professional financial advisor in order to
make their own investment decisions
This report or any information contained herein have been prepared by the CMBIS solely for the purpose of supplying information to the clients of
CMBIS or its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security
or any interest in securities or enter into any transaction  Neither CMBIS nor any of its affiliates shareholders agents consultants directors officers
or employees shall be liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the information
contained in this report  Anyone making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available
CMBIS provides the information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice
CMBIS may issue other publications having information and or conclusions different from this report  These publications reflect different assumption
andor on behalf of its clients from time to time Investors should assume that CMBIS does or seeks to have investment banking or other business
the objectivity of this report and CMBIS will not assume any responsibility in respect thereof This report is for the use of intended recipients only
and this publication may not be reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written
consent of CMBIS
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005 (as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies
Unincorporated Associations etc) of the Order and may not be provided to any other person without the prior written consent of CMBIS
For recipients of this document in the United States
This report is intended for distribution in the United States to major US institutional investors as defined in Rule 15a-6 under the US Securities
Exchange Act of 1934 and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy
of this research report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser
as defined in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute
reports produced by its respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of
the Financial Advisers Regulations Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or
an Institutional Investor as defined in the Securities and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents
of the report to such persons only to the extent required by law Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising
from or in connection with the report